Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Accumulated Expenses (2016 - 2026)

Heron Therapeutics filings provide 16 years of Accumulated Expenses readings, the most recent being $6.4 million for Q1 2026.

  • On a quarterly basis, Accumulated Expenses fell 0.95% to $6.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $6.4 million, a 0.95% decrease, with the full-year FY2025 number at $9.3 million, up 56.93% from a year prior.
  • Accumulated Expenses hit $6.4 million in Q1 2026 for Heron Therapeutics, down from $9.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $16.3 million in Q2 2022 to a low of $2.1 million in Q4 2022.
  • Median Accumulated Expenses over the past 5 years was $8.5 million (2024), compared with a mean of $8.5 million.
  • Biggest five-year swings in Accumulated Expenses: tumbled 86.02% in 2022 and later surged 150.93% in 2024.
  • Heron Therapeutics' Accumulated Expenses stood at $2.1 million in 2022, then grew by 10.31% to $2.4 million in 2023, then surged by 150.93% to $5.9 million in 2024, then surged by 56.93% to $9.3 million in 2025, then crashed by 31.07% to $6.4 million in 2026.
  • The last three reported values for Accumulated Expenses were $6.4 million (Q1 2026), $9.3 million (Q4 2025), and $8.7 million (Q3 2025) per Business Quant data.